Xbrane Biopharma Swells In Oncology With Keytruda And Darzalex Projects
With Opdivo Biosimilar, Three Products ‘Could Be Launched In 2028-2029’
Executive Summary
Xbrane Biopharma held a webcast with investors to mark the Swedish firm’s announcement to initiate development of two major new oncology biosimilar projects. CEO Martin Åmark delved into detail on how the programs fit into the company’s wider pipeline and Xbrane’s rigorous selection process.
You may also be interested in...
Formycon Reveals Keytruda Biosimilar In The Works
Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.
Xbrane Pauses Primm Divestment Process
Xbrane Biopharma has paused the process of divesting its Primm Pharma subsidiary, developer of the Spherotide long-acting triptorelin formulation, after failing to reach a final agreement with the expected acquirer, Italy’s NewFaDem.
Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar
Xbrane Biopharma and Biogen have struck a licensing deal for Xbrane’s Xcimzane certolizumab pegol proposed biosimilar rival to Cimzia. In the wake of the announcement, Xbrane CEO Martin Åmark offered details on the partnership as well as the product’s commercial potential.